Kyntra Bio, Inc. — Form 8-K Summary
Reporting context: The filing reports a Nasdaq continued-listing determination dated September 30, 2026. It is not a quarterly or annual earnings report and provides no current-period revenue, profit, cash flow, margin, debt, or liquidity figures.
Nasdaq Listing Status
- Nasdaq staff determined that Kyntra Bio had not demonstrated compliance with Listing Rule 5450(b) by the September 29, 2026 deadline and decided to delist the company’s common stock from the Nasdaq Global Select Market.
- The company timely requested a hearing before a Nasdaq Hearings Panel and is seeking additional time to regain compliance. The request stays suspension of the securities and filing of Form 25-NSE while the Panel considers the matter.
- Kyntra Bio’s common stock, ticker KYNB, is expected to remain listed and trading on Nasdaq pending the Panel’s written decision. An extension, if granted, could be up to 180 days from the staff determination.
Prior Notice and Compliance Requirements
Nasdaq notified the company on April 2, 2026 that it did not meet Rule 5450(b)(3)(A), which requires at least $50 million in both total assets and total revenue for the most recently completed fiscal year or two of the three most recently completed fiscal years. The company also did not meet the alternative stockholders’ equity or market value of listed securities standards under Rule 5450(b).
Outlook and Risks
The company said it is preparing a compliance plan for the Panel. It cautioned that there is no assurance the Panel will allow continued listing or that the company will regain compliance within any extension period. The filing provides no financial outlook or quantified liquidity information.
Important Facts to Verify
- The Panel’s decision and whether it grants an extension or continued-listing relief.
- The specific compliance plan, the financial measures supporting it, and the company’s progress toward Nasdaq’s requirements.
- Any subsequent Nasdaq notices, trading-status changes, or additional disclosures about the company’s financial condition.